Immunocellular Therapeutics Stock Net Income

IMUCDelisted Stock  USD 0.47  0.00  0.00%   
ImmunoCellular Therapeutics fundamentals help investors to digest information that contributes to ImmunoCellular Therapeutics' financial success or failures. It also enables traders to predict the movement of ImmunoCellular Pink Sheet. The fundamental analysis module provides a way to measure ImmunoCellular Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoCellular Therapeutics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ImmunoCellular Therapeutics Company Net Income Analysis

ImmunoCellular Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current ImmunoCellular Therapeutics Net Income

    
  (5.15 M)  
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, ImmunoCellular Therapeutics reported net income of (5.15 Million). This is 101.51% lower than that of the Biotechnology sector and 107.35% lower than that of the Health Care industry. The net income for all United States stocks is 100.9% higher than that of the company.

ImmunoCellular Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.
ImmunoCellular Therapeutics is currently under evaluation in net income category among its peers.

ImmunoCellular Fundamentals

About ImmunoCellular Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ImmunoCellular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in ImmunoCellular Pink Sheet

If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Global Correlations
Find global opportunities by holding instruments from different markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal